PURPOSE: To identify the perspectives from healthcare providers about the limitations in referral, diagnosis, and treatment of lung cancer (LC) patients. METHODS: A cross-sectional study through an Internet-based survey was addressed to physicians of multidisciplinary teams in charge of LC patients from Cuba, Curacao, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Jamaica, Panama, and Trinidad and Tobago. The questions focused on physicians' perspectives concerning waiting times and the availability of diagnostic and staging procedures in their settings, as well as the access to systemic therapies and continuous medical education (CME). RESULTS: A total of 152 physicians responded to the online questionnaire (response rate 24.9%). Delays in biopsy results were the main barrier for LC diagnosis as identified by 48.2% of the respondents, followed by patients not being referred in time (31.3%), delays for staging procedures (11.4%), and time taken for biopsy (9%). Almost one-half of physicians perceived that patients are diagnosed in advanced stages. A total of 29 respondent physicians (19.1%) reported limited access to immunohistochemical or genetic analysis for common mutations. Although 73 physicians (48.0%) confirmed that their centers provided radiotherapy and systemic therapy for their patients, immunotherapy was not available in the institutions of 30 physicians (19.7%). A total of 42 practitioners (27.6%) reported that they did not have access to CME on LC topics due to working or budget restrictions. CONCLUSIONS: This study revealed among respondents the main barriers for an appropriate management of LC patients in the Central American and Caribbean Region. Further studies must validate these findings.
PURPOSE: To identify the perspectives from healthcare providers about the limitations in referral, diagnosis, and treatment of lung cancer (LC) patients. METHODS: A cross-sectional study through an Internet-based survey was addressed to physicians of multidisciplinary teams in charge of LC patients from Cuba, Curacao, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Jamaica, Panama, and Trinidad and Tobago. The questions focused on physicians' perspectives concerning waiting times and the availability of diagnostic and staging procedures in their settings, as well as the access to systemic therapies and continuous medical education (CME). RESULTS: A total of 152 physicians responded to the online questionnaire (response rate 24.9%). Delays in biopsy results were the main barrier for LC diagnosis as identified by 48.2% of the respondents, followed by patients not being referred in time (31.3%), delays for staging procedures (11.4%), and time taken for biopsy (9%). Almost one-half of physicians perceived that patients are diagnosed in advanced stages. A total of 29 respondent physicians (19.1%) reported limited access to immunohistochemical or genetic analysis for common mutations. Although 73 physicians (48.0%) confirmed that their centers provided radiotherapy and systemic therapy for their patients, immunotherapy was not available in the institutions of 30 physicians (19.7%). A total of 42 practitioners (27.6%) reported that they did not have access to CME on LC topics due to working or budget restrictions. CONCLUSIONS: This study revealed among respondents the main barriers for an appropriate management of LC patients in the Central American and Caribbean Region. Further studies must validate these findings.
Entities:
Keywords:
Caribbean region; Central America; Lung cancer; Referral and consultation
Authors: Paul E Goss; Brittany L Lee; Tanja Badovinac-Crnjevic; Kathrin Strasser-Weippl; Yanin Chavarri-Guerra; Jessica St Louis; Cynthia Villarreal-Garza; Karla Unger-Saldaña; Mayra Ferreyra; Márcio Debiasi; Pedro E R Liedke; Diego Touya; Gustavo Werutsky; Michaela Higgins; Lei Fan; Claudia Vasconcelos; Eduardo Cazap; Carlos Vallejos; Alejandro Mohar; Felicia Knaul; Hector Arreola; Rekha Batura; Silvana Luciani; Richard Sullivan; Dianne Finkelstein; Sergio Simon; Carlos Barrios; Rebecca Kightlinger; Andres Gelrud; Vladimir Bychkovsky; Gilberto Lopes; Stephen Stefani; Marcelo Blaya; Fabiano Hahn Souza; Franklin Santana Santos; Alberto Kaemmerer; Evandro de Azambuja; Andres Felipe Cardona Zorilla; Raul Murillo; Jose Jeronimo; Vivien Tsu; Andre Carvalho; Carlos Ferreira Gil; Cinthya Sternberg; Alfonso Dueñas-Gonzalez; Dennis Sgroi; Mauricio Cuello; Rodrigo Fresco; Rui Manuel Reis; Guiseppe Masera; Raúl Gabús; Raul Ribeiro; Renata Knust; Gustavo Ismael; Eduardo Rosenblatt; Berta Roth; Luisa Villa; Argelia Lara Solares; Marta Ximena Leon; Isabel Torres-Vigil; Alfredo Covarrubias-Gomez; Andrés Hernández; Mariela Bertolino; Gilberto Schwartsmann; Sergio Santillana; Francisco Esteva; Luis Fein; Max Mano; Henry Gomez; Marc Hurlbert; Alessandra Durstine; Gustavo Azenha Journal: Lancet Oncol Date: 2013-04 Impact factor: 41.316
Authors: Neal I Lindeman; Philip T Cagle; Dara L Aisner; Maria E Arcila; Mary Beth Beasley; Eric H Bernicker; Carol Colasacco; Sanja Dacic; Fred R Hirsch; Keith Kerr; David J Kwiatkowski; Marc Ladanyi; Jan A Nowak; Lynette Sholl; Robyn Temple-Smolkin; Benjamin Solomon; Lesley H Souter; Erik Thunnissen; Ming S Tsao; Christina B Ventura; Murry W Wynes; Yasushi Yatabe Journal: Arch Pathol Lab Med Date: 2018-01-22 Impact factor: 5.534
Authors: Yung-Hung Luo; Lei Luo; Jason A Wampfler; Yi Wang; Dan Liu; Yuh-Min Chen; Alex A Adjei; David E Midthun; Ping Yang Journal: Lancet Oncol Date: 2019-06-26 Impact factor: 41.316
Authors: J Dunn; G Garvey; P C Valery; D Ball; K M Fong; S Vinod; D L O'Connell; S K Chambers Journal: Support Care Cancer Date: 2016-10-10 Impact factor: 3.603
Authors: Luis E Raez; Amanda Nogueira; Edgardo S Santos; Ricardo Sales Dos Santos; Juliana Franceschini; David Arias Ron; Mark Block; Nise Yamaguchi; Christian Rolfo Journal: J Glob Oncol Date: 2018-09